A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients

Hai Huang,Ao Liu,Yiming Liang,Yaqun Xin,Jiacheng Liu,Yining Hao,Da Huang,Lu Chen,Wei Li,Guangliang Jiang,Yuhua Huang,Yaoting Xu,Jie Zhang,Tonghui Ma,Danfeng Xu,Yi Gao
DOI: https://doi.org/10.1186/s12916-023-03065-5
IF: 9.3
2023-09-21
BMC Medicine
Abstract:Currently, the clinical strategy for diagnosis of non-muscle invasive bladder cancer (NMIBC) such as cystoscopy and cytology are invasive and/or with limited accuracy. OncoUrine, a urinary assay for mutation and methylation biomarkers, have showed a high accuracy in the detection of upper tract urinary carcinoma (UTUC) patients with hematuria. The aim of this study is to evaluate the performance of OncoUrine in diagnosis of NMIBC patients.
medicine, general & internal
What problem does this paper attempt to address?